CoChat

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Open access

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

Abstract

Complex tumor microenvironmental (TME) features influence the outcome of cancer immunotherapy (IO). Here we perform immunogenomic analyses on 67 intratumor sub-regions of a PD-1 inhibitor-resistant melanoma tumor and 2 additional metastases arising over 8 years, to characterize TME interactions. We identify spatially distinct evolution of copy number alterations influencing local immune composition. Sub-regions with chromosome 7 gain display a relative lack of leukocyte infiltrate but evidence of neutrophil activation, recapitulated in The Cancer Genome Atlas (TCGA) samples, and associated with lack of response to IO across three clinical cohorts. Whether neutrophil activation represents cause or consequence of local tumor necrosis requires further study. Analyses of T-cell clonotypes reveal the presence of recurrent priming events manifesting in a dominant T-cell clonotype over many years. Our findings highlight the links between marked levels of genomic and immune heterogeneity within the physical space of a tumor, with implications for biomarker evaluation and immunotherapy response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-15538-9

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Genomic inter- and intratumoral heterogeneity in a heavily treated melanoma patient are driven by copy number alterations. a Timeline of treatments and surgical sampling of three distinct melanoma tumors from a long-term surviving patient with largely treatment unresponsive metastatic melanoma. Treatment modality is indicated by color (red, chemotherapy; blue, targeted therapy; purple, immunotherapy). Molecularly profiled lesions are indicated: index left lower lobe (LLL) lung metastasis (lesion 1), progressing ventral abdominal wall mass (lesion 2), and slowly progressing right gluteal mass (lesion 3). b Sectioning and use of the on-PD-1 inhibitor abdominal wall lesion. The tumor was oriented by lateral inking (red, left; blue, right), sliced, and laid on a grid. The odd-numbered slices were processed for FFPE and used for immunohistochemistry, whereas the even-numbered slices were fresh-frozen and used for genomic and proteomic analyses (whole exome sequencing (WES), RNA sequencing, TCR sequencing, reverse-phase protein array (RPPA)). c Functional hypomorphism of the identified JAK1 mutation (JAK1P1044S) was identified by Ba/F3 transformation assay. Also shown are known oncogenic JAK1 variants (JAK1R879H, JAK1S1043I, JAK1A634D), wild-type JAK1, a truncating JAK1 hypomorph (JAK1W1047*), and oncogenic PIK3CA variants. d Copy number alterations in each region of the tumor are shown in the chromosome coordinate as log2-transformed copy number probe intensities R (observed intensity/reference intensity); copy number gains are shown as red and copy number losses as blue.
Fig. 1 Genomic inter- and intratumoral heterogeneity in a heavily treated melanoma patient are driven by copy number alterations. a Timeline of treatments and surgical sampling of three distinct melanoma tumors from a long-term surviving patient with largely treatment unresponsive metastatic melanoma. Treatment modality is indicated by color (red, chemotherapy; blue, targeted therapy; purple, immunotherapy). Molecularly profiled lesions are indicated: index left lower lobe (LLL) lung metastasis (lesion 1), progressing ventral abdominal wall mass (lesion 2), and slowly progressing right gluteal mass (lesion 3). b Sectioning and use of the on-PD-1 inhibitor abdominal wall lesion. The tumor was oriented by lateral inking (red, left; blue, right), sliced, and laid on a grid. The odd-numbered slices were processed for FFPE and used for immunohistochemistry, whereas the even-numbered slices were fresh-frozen and used for genomic and proteomic analyses (whole exome sequencing (WES), RNA sequencing, TCR sequencing, reverse-phase protein array (RPPA)). c Functional hypomorphism of the identified JAK1 mutation (JAK1P1044S) was identified by Ba/F3 transformation assay. Also shown are known oncogenic JAK1 variants (JAK1R879H, JAK1S1043I, JAK1A634D), wild-type JAK1, a truncating JAK1 hypomorph (JAK1W1047*), and oncogenic PIK3CA variants. d Copy number alterations in each region of the tumor are shown in the chromosome coordinate as log2-transformed copy number probe intensities R (observed intensity/reference intensity); copy number gains are shown as red and copy number losses as blue.CC BY · PubMed Central
Fig. 2 Immune-driven transcriptional heterogeneity implicates diverse immune cell populations and highly localized immune activation or suppression. a Unsupervised hierarchical clustering based on the top 1000 most variant (mean absolute deviation) genes across all samples of the on-PD-1 inhibitor tumor, demonstrating limited associations between clustering of samples and tumor location based on the general transcriptome, but apparent association between high immune infiltrate and location at the tumor margin. b Heatmap of immune signature gene sets (from Rooney et al.13) across tumor sub-regions demonstrate dispersed pockets of immune activation or suppression throughout the tumor, wherein immune-high samples (e.g., 4A1/4A2, 6A5, and 8A6) are physically distant from each other within the tumor mass. IHC-based immune infiltrate and ESTIMATE immune scores (top) and IHC-based tumor sample location (bottom) are indicated. c Immunohistochemical marker inter-correlations demonstrating generally diverse representation of immune cell types when infiltrates are present. Data are Spearman’s correlation values (with Benjamini–Hochberg correction; only p < 0.05 are shown) indicated according to the color scale shown. d Correlation of most variably abundant proteins measured by reverse-phase protein array, revealing two main modules of highly correlated molecules. Proteins displaying statistically significant (FDR p < 0.10) correlation with immune infiltrate are indicated by * and color (blue = anti-correlated with immune infiltrate, red = directly correlated with immune infiltrate). Data are Spearman’s correlation values (with Benjamini–Hochberg correction; only p < 0.05 are shown) indicated according to the color scale shown. e Sample-wide similarity of immune activity was estimated by calculation of the distance matrix between samples using the immune activation signature expression data; lines connect samples in the top quartile of similarity scores, demonstrating global immune signature similarities that are not restricted by intratumoral location. f Three-dimensional spatial mapping of subregion Cytolytic activity signature, Type-I IFN response signature and Co-inhibition, T-cell signature scores derived from transcriptomic data, in the manner of Rooney et al.13. Data map the geometric mean of genes included in each gene set onto three-dimensional space representing the tumor slices, with color and height indicating expression value (higher expression = red peaks, lower expression = blue troughs).
Fig. 2 Immune-driven transcriptional heterogeneity implicates diverse immune cell populations and highly localized immune activation or suppression. a Unsupervised hierarchical clustering based on the top 1000 most variant (mean absolute deviation) genes across all samples of the on-PD-1 inhibitor tumor, demonstrating limited associations between clustering of samples and tumor location based on the general transcriptome, but apparent association between high immune infiltrate and location at the tumor margin. b Heatmap of immune signature gene sets (from Rooney et al.13) across tumor sub-regions demonstrate dispersed pockets of immune activation or suppression throughout the tumor, wherein immune-high samples (e.g., 4A1/4A2, 6A5, and 8A6) are physically distant from each other within the tumor mass. IHC-based immune infiltrate and ESTIMATE immune scores (top) and IHC-based tumor sample location (bottom) are indicated. c Immunohistochemical marker inter-correlations demonstrating generally diverse representation of immune cell types when infiltrates are present. Data are Spearman’s correlation values (with Benjamini–Hochberg correction; only p < 0.05 are shown) indicated according to the color scale shown. d Correlation of most variably abundant proteins measured by reverse-phase protein array, revealing two main modules of highly correlated molecules. Proteins displaying statistically significant (FDR p < 0.10) correlation with immune infiltrate are indicated by * and color (blue = anti-correlated with immune infiltrate, red = directly correlated with immune infiltrate). Data are Spearman’s correlation values (with Benjamini–Hochberg correction; only p < 0.05 are shown) indicated according to the color scale shown. e Sample-wide similarity of immune activity was estimated by calculation of the distance matrix between samples using the immune activation signature expression data; lines connect samples in the top quartile of similarity scores, demonstrating global immune signature similarities that are not restricted by intratumoral location. f Three-dimensional spatial mapping of subregion Cytolytic activity signature, Type-I IFN response signature and Co-inhibition, T-cell signature scores derived from transcriptomic data, in the manner of Rooney et al.13. Data map the geometric mean of genes included in each gene set onto three-dimensional space representing the tumor slices, with color and height indicating expression value (higher expression = red peaks, lower expression = blue troughs).CC BY · PubMed Central
Fig. 3 Transcriptomic analysis demonstrates considerable ITH underlying convergent immune phenotypes. a Volcano plot of differentially expressed genes comparing high vs. low immune infiltrate regions across the tumor core and margins. Vertical red lines indicate a minimum twofold change in expression value; horizontal red line indicates the adjusted p-value threshold of <1e-8. b Representative IHC sections demonstrating matched tumor content (SOX10 stain, above) and immune infiltration (CD8 stain, below) illustrating substantial variation of local CD8 T-cell content ranging from low (arrows) to high (arrowheads). c Gene connection network of genes upregulated in immune-infiltrated samples that contribute to highly enriched GO terms/pathways, showing substantial connectivity. d Functional enrichment network showing diverse representation of immune cell pathways and functions in the immune infiltrate-derived differentially expressed genes, dominated by highly inter-connected T and B-lymphocyte-related terms. e Representative IHC images of a para-tumoral lymphoid structure present in section 1B, demonstrating absence of tumor cells (SOX10) but mixed populations of CD4+, CD8+, and PAX5+ lymphocytes. Magnification ×10. f Single-sample gene-set enrichment analysis demonstrating spatially discontiguous enrichment of functionally relevant gene sets throughout the tumor. IHC-based estimate of immune infiltrate (top) and sample location (bottom) are indicated. g Immunostained tumor tissue revealing restriction of tumor cell phospho-ERK1/2 expression (brown staining) to cells located at or immediately subjacent to the tumor cell surface. Arrowheads: tumor-surrounding tissue interface. Magnification ×10.
Fig. 3 Transcriptomic analysis demonstrates considerable ITH underlying convergent immune phenotypes. a Volcano plot of differentially expressed genes comparing high vs. low immune infiltrate regions across the tumor core and margins. Vertical red lines indicate a minimum twofold change in expression value; horizontal red line indicates the adjusted p-value threshold of <1e-8. b Representative IHC sections demonstrating matched tumor content (SOX10 stain, above) and immune infiltration (CD8 stain, below) illustrating substantial variation of local CD8 T-cell content ranging from low (arrows) to high (arrowheads). c Gene connection network of genes upregulated in immune-infiltrated samples that contribute to highly enriched GO terms/pathways, showing substantial connectivity. d Functional enrichment network showing diverse representation of immune cell pathways and functions in the immune infiltrate-derived differentially expressed genes, dominated by highly inter-connected T and B-lymphocyte-related terms. e Representative IHC images of a para-tumoral lymphoid structure present in section 1B, demonstrating absence of tumor cells (SOX10) but mixed populations of CD4+, CD8+, and PAX5+ lymphocytes. Magnification ×10. f Single-sample gene-set enrichment analysis demonstrating spatially discontiguous enrichment of functionally relevant gene sets throughout the tumor. IHC-based estimate of immune infiltrate (top) and sample location (bottom) are indicated. g Immunostained tumor tissue revealing restriction of tumor cell phospho-ERK1/2 expression (brown staining) to cells located at or immediately subjacent to the tumor cell surface. Arrowheads: tumor-surrounding tissue interface. Magnification ×10.CC BY · PubMed Central
Fig. 4 T-cell repertoire dynamics reveal high ITH, potential for long-term clonal persistence and irregular intratumoral movement. a Heatmaps of the 560 most variably expressed genes (based on median absolute deviation) across the transcriptome dataset for which matched methylation and copy number data were available, indicating distinct sample-wise clustering patterns within each dataset and generally unidirectional methylation patterns within samples. Data are log2-transformed counts (gene expression), β-values (methylation), and log2(probe intensity = observed intensity/reference intensity) (copy number), z-scored within each data type. b Correlation of copy number (upper panel) and methylation (lower panel) with transcript expression for the most variable genes on chromosome 7 showing mostly positive correlations for CNA and mostly negative correlations for methylation as expected. Three genes (indicated in blue, lower panel) showed discordant correlations for both CNA and methylation. c Tanglegram showing relationships between the sample clustering obtained independently from each of the copy number, methylation, and transcriptome datasets for samples represented in all datasets. Entaglement values (range 0–1) indicate moderate lack of cluster structure concordance, indicative in this context of significant additional (unmeasured) factors contributing to the regulation of mRNA expression. Immune status of each subregion sample is indicated in color. d T-cell receptor-Vβ (TCR) clonality (range 0–1) varied considerably between clinically relevant time points, between tumors and the peripheral blood, and spatially within the on-PD-1 inhibitor tumor. Samples with clonality > 0.1 are highlighted in orange. e Top ten most abundant TCR clonotype proportions (i.e., fraction of total identified TCR clonotypes) in each sample are represented as stacked bar plots. The topmost abundant clone is colored at the top of the bar, with each color representing a unique clonotype that may be shared between samples. Clonotypes 2–5 and 6–10 are colored in light blue and deep blue, respectively. f Morisita overlap index (MOI, range 0–1) values of TCR repertoires comparing the pretreatment sample, peripheral blood samples, on-PD-1 inhibitor sample (each subregion), and a post-PD-1 inhibitor sample were used to compare the overlap in shared nucleotypes in the TCR repertoire identified in each sample. Higher MOI indicates a greater proportion of shared TCR sequences. Within the on-PD-1 inhibitor sample, TCR clonotypes present in section 8 were largely restricted to this geographic location, which was notably highly necrotic. There was considerable sharing of clonotypes between sections 4 and 6, and to a lesser degree between 2, 4, and 6, suggesting a greater degree of physical movement of T cells between these sections. g tSNE plot of TIL populations. The majority of the cells fell into an activated cytotoxic T-cell lymphocyte, CD4 T cell, and checkpoint-inhibited T-cell phenotype. h Marker gene expression levels across TIL clusters. Relative expression of key marker genes associated with a cytotoxic T-cell phenotype (CD8, GZMA, and PRF1), CD4 phenotype (CD4 and IL7R), and a multiply checkpoint-inhibited phenotype (FOXP3, CTLA-4, GITR, and ICOS) are overlaid on the tSNE clusters.
Fig. 4 T-cell repertoire dynamics reveal high ITH, potential for long-term clonal persistence and irregular intratumoral movement. a Heatmaps of the 560 most variably expressed genes (based on median absolute deviation) across the transcriptome dataset for which matched methylation and copy number data were available, indicating distinct sample-wise clustering patterns within each dataset and generally unidirectional methylation patterns within samples. Data are log2-transformed counts (gene expression), β-values (methylation), and log2(probe intensity = observed intensity/reference intensity) (copy number), z-scored within each data type. b Correlation of copy number (upper panel) and methylation (lower panel) with transcript expression for the most variable genes on chromosome 7 showing mostly positive correlations for CNA and mostly negative correlations for methylation as expected. Three genes (indicated in blue, lower panel) showed discordant correlations for both CNA and methylation. c Tanglegram showing relationships between the sample clustering obtained independently from each of the copy number, methylation, and transcriptome datasets for samples represented in all datasets. Entaglement values (range 0–1) indicate moderate lack of cluster structure concordance, indicative in this context of significant additional (unmeasured) factors contributing to the regulation of mRNA expression. Immune status of each subregion sample is indicated in color. d T-cell receptor-Vβ (TCR) clonality (range 0–1) varied considerably between clinically relevant time points, between tumors and the peripheral blood, and spatially within the on-PD-1 inhibitor tumor. Samples with clonality > 0.1 are highlighted in orange. e Top ten most abundant TCR clonotype proportions (i.e., fraction of total identified TCR clonotypes) in each sample are represented as stacked bar plots. The topmost abundant clone is colored at the top of the bar, with each color representing a unique clonotype that may be shared between samples. Clonotypes 2–5 and 6–10 are colored in light blue and deep blue, respectively. f Morisita overlap index (MOI, range 0–1) values of TCR repertoires comparing the pretreatment sample, peripheral blood samples, on-PD-1 inhibitor sample (each subregion), and a post-PD-1 inhibitor sample were used to compare the overlap in shared nucleotypes in the TCR repertoire identified in each sample. Higher MOI indicates a greater proportion of shared TCR sequences. Within the on-PD-1 inhibitor sample, TCR clonotypes present in section 8 were largely restricted to this geographic location, which was notably highly necrotic. There was considerable sharing of clonotypes between sections 4 and 6, and to a lesser degree between 2, 4, and 6, suggesting a greater degree of physical movement of T cells between these sections. g tSNE plot of TIL populations. The majority of the cells fell into an activated cytotoxic T-cell lymphocyte, CD4 T cell, and checkpoint-inhibited T-cell phenotype. h Marker gene expression levels across TIL clusters. Relative expression of key marker genes associated with a cytotoxic T-cell phenotype (CD8, GZMA, and PRF1), CD4 phenotype (CD4 and IL7R), and a multiply checkpoint-inhibited phenotype (FOXP3, CTLA-4, GITR, and ICOS) are overlaid on the tSNE clusters.CC BY · PubMed Central
Fig. 5 Chromosome 7 gain is associated with an unfavorable immune environment driven by neutrophil signatures that characterize non-responders to immune checkpoint blockade. a, b Chromosome 7 gain sub-regions of the melanoma mass progressing during anti-PD-1 therapy revealed lesser suppressive neutrophil signatures compared with sub-regions unaffected by chromosome 7 gains. Scores shown represent geometric mean log2-transformed counts of genes within the GO terms indicated (see also Supplementary Data 7). Plots include two-sample t-test comparison with accompanying significance values. c Samples affected by whole-chromosome 7 gains within The Cancer Genome Atlas skin cutaneous melanoma (SKCM) dataset revealed prominent differential upregulation of genes involved in neutrophil activation signatures revealed by Gene Ontology term enrichments. Gene ratios indicate the ratio of representation of input genes within the indicated GO term gene set relative to all queried GO term gene sets. Top enriched pathways are displayed after Benjamini–Hochberg correction for multiple testing. d Connected gene network of genes involved in major GO term enrichments within chromosome 7 gain TCGA SKCM samples. e–g Differentially expressed genes contrasting responders vs. non-responders to immune checkpoint blockade agents in publicly available datasets revealed consistent GO term enrichments for neutrophil activation signatures. Top enriched pathways are displayed after Benjamini–Hochberg correction for multiple testing. e Van Allen et al.5, anti-CTLA-4 dataset; f Hugo et al.27, anti-PD-1 dataset; g Riaz et al.26, anti-PD-1 dataset. h Heatmap of genes found recurrently enriched across TCGA SKCM chromosome 7 gain and clinical non-responder samples showing relative enrichment of each gene across the datasets as a scaled value.
Fig. 5 Chromosome 7 gain is associated with an unfavorable immune environment driven by neutrophil signatures that characterize non-responders to immune checkpoint blockade. a, b Chromosome 7 gain sub-regions of the melanoma mass progressing during anti-PD-1 therapy revealed lesser suppressive neutrophil signatures compared with sub-regions unaffected by chromosome 7 gains. Scores shown represent geometric mean log2-transformed counts of genes within the GO terms indicated (see also Supplementary Data 7). Plots include two-sample t-test comparison with accompanying significance values. c Samples affected by whole-chromosome 7 gains within The Cancer Genome Atlas skin cutaneous melanoma (SKCM) dataset revealed prominent differential upregulation of genes involved in neutrophil activation signatures revealed by Gene Ontology term enrichments. Gene ratios indicate the ratio of representation of input genes within the indicated GO term gene set relative to all queried GO term gene sets. Top enriched pathways are displayed after Benjamini–Hochberg correction for multiple testing. d Connected gene network of genes involved in major GO term enrichments within chromosome 7 gain TCGA SKCM samples. e–g Differentially expressed genes contrasting responders vs. non-responders to immune checkpoint blockade agents in publicly available datasets revealed consistent GO term enrichments for neutrophil activation signatures. Top enriched pathways are displayed after Benjamini–Hochberg correction for multiple testing. e Van Allen et al.5, anti-CTLA-4 dataset; f Hugo et al.27, anti-PD-1 dataset; g Riaz et al.26, anti-PD-1 dataset. h Heatmap of genes found recurrently enriched across TCGA SKCM chromosome 7 gain and clinical non-responder samples showing relative enrichment of each gene across the datasets as a scaled value.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 92 references

Cited by

See all 28

Metadata

Authors
Mitra, A., Andrews, M. C., Roh, W., De Macedo, M. P., Hudgens, C. W., Carapeto, F., Singh, S., Reuben, A., Wang, F., Mao, X., Song, X., Wani, K., Tippen, S., Ng, K.-S., Schalck, A., Sakellariou-Thompson, D. A., Chen, E., Reddy, S. M., Spencer, C. N., Wiesnoski, D., Little, L. D., Gumbs, C., Cooper, Z. A., Burton, E. M., Hwu, P., Davies, M. A., Zhang, J., Bernatchez, C., Navin, N., Sharma, P., Allison, J. P., Wargo, J. A., Yee, C., Tetzlaff, M. T., Hwu, W.-J., Lazar, A. J., & Futreal, P. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Broad Institute (US)
  • Parker Institute for Cancer Immunotherapy (US)
  • AstraZeneca (United States) (US)
Corresponding author
Futreal, P. Andrew
Venue
Nature Communications
Published
2020-04-15
Volume
11
Issue
1
Pages
1839-1839
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3016947983
Cited by
27
References
92
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 6 · 2022: 4 · 2021: 7 · 2020: 3
FWCI
1.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Cancer Prevention and Research Institute of Texas (RP170067, R1205)
  • Gilead Sciences
  • Parker Institute for Cancer Immunotherapy
  • Myriad Genetics
  • Astellas Pharma
  • Genentech
  • EMD Serono
  • University of Texas MD Anderson Cancer Center (#CA16672, RP170067)
  • Merck Sharp and Dohme
  • Kite Pharma
  • Medical Research Council
  • National Health and Medical Research Council (1148680)
  • National Cancer Institute (CA-16672, P30CA016672)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR065971)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
melanoma, tumor microenvironment, spatial heterogeneity, neutrophil activation, anti-PD-1 resistance, copy number alterations, chromosome 7 gain, T cell clonotypes, T cell priming, immunotherapy response, metastasis, genomic heterogeneity, immune heterogeneity
MeSH terms
Humans, Melanoma, Mutation, Biomarkers, Tumor, Neutrophil Activation, Genomics, DNA Copy Number Variations, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. https://app.cochat.ai/papers/10.1038/s41467-020-15538-9
The paper
Mitra, A., Andrews, M. C., Roh, W., De Macedo, M. P., Hudgens, C. W., Carapeto, F., Singh, S., Reuben, A., Wang, F., Mao, X., Song, X., Wani, K., Tippen, S., Ng, K.-S., Schalck, A., Sakellariou-Thompson, D. A., Chen, E., Reddy, S. M., Spencer, C. N., . . . Futreal, P. A. (2020). Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications. https://doi.org/10.1038/s41467-020-15538-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.